Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Standard Therapy for Exudative Age-Related Macular Degeneration
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 142
- 试验地点
- 1
- 主要终点
- Visual Acuity
研究概览
简要总结
Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks. In contrast, clinical trials of a soluble VEGF receptor, Aflibercept/VEGF Trap-Eye (Eylea, Regeneron Pharmaceuticals) have demonstrated maintained anatomic and visual improvement with many fewer injections (typically monthly injections for 3 months, followed by every-other-month injections, and as few as 5 injections a year). The purpose of this study is to determine whether patients who have switched from ranibizumab to VEGF Trap-Eye have comparable results.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients older than the age of 50 determined by a retinal physician at the Byers Eye Institute at Stanford to have exudative AMD requiring treatment.
- •Patients with an established diagnosis of exudative AMD who have been maintained on a regimen of intravitreal ranibizumab injections.
- •Postmenopausal or negative pregnancy test
- •Patients with an established diagnois of exidative AMD who have been switched from intravitreal ranibizumab to intravitreal VEGF Trap-EYE.
排除标准
- •Patients with any previous or concurrent history of treatment of other retinal diseases with pharmacologic agents other than ranibizumab, including verteporfin photodynamic therapy, bevacizumab, triamcinolone, or dexamethasone.
- •Patients with prior history of vitrectomy surgery in the study eye.
- •Patients enrolled in any previous or current clinical trial or study of any medication for AMD or any other retinal vascular disease, including diabetic retinopathy or retinal vein occlusion.
- •Ocular media opacity precluding proper retinal imaging
- •Inadequate pupillary dilation to achieve proper retinal imaging
- •Concurrent use of systemic anti-VEGF agents
- •CNV due to other causes, including histoplasmosis, uveitis, trauma, or myopia
- •Active or recent (< 4 weeks) or recurrent inflammation in the eye
- •Current vitreous hemorrhage in the study eye limiting visualization of the fundus
- •Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
- •Untreated glaucoma with IOP > 25 in the eye
- •Other ocular diseases that can compromise the visual acuity of the study eye such as amblyopia and anterior ischemic optic neuropathy
- •Pregnancy or lactation
- •History of other disease, exam finding, or clinical laboratory that contraindicates the use the drug
- •Current treatment for active systemic infection
- •Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, pulmonary, renal, hepatic, endocrine, or GI disorders
- •History of recurrent significant infections or bacterial infections
- •Inability to comply with study or follow-up procedure
研究组 & 干预措施
Patients with Exudative Age-Related Macular Degeneration
Patients with eAMD who received intravitreal thearpy
干预措施: Intravitreal injection of Aflibercept (Drug)
结局指标
主要结局
Visual Acuity
时间窗: 1 year
次要结局
未报告次要终点
研究者
Theodore Leng
Clinical Assistant Professor of Ophthalmology
Stanford University